Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis

被引：0

作者：

Vasconcelos, Zanair Soares ^{[1
,2
]}

Salem, Hany Abdulateif ^{[3
]}

Veiga, Samia Pimenta ^{[1
]}

de Lima, Fabiola Estefany Botelho ^{[4
]}

Goncalves, Cesar Rogerio da Silva ^{[5
]}

dos Santos, Eliane Carvalho ^{[2
]}

Brandao, Alba Regina Jorge ^{[1
]}

Couceiro, Katia Nascimento ^{[1
,6
]}

Guerra, Jorge Augusto de Oliveira ^{[1
,7
]}

Guerra, Maria das Gracas Vale Barbosa ^{[1
,6
,7
]}

机构：

[1] Univ Estado Amazonas, Programa Posgrad Stricto Sensu Med Trop, Manaus, AM, Brazil

[2] Ctr Instrucao Guerra Selva, Manaus, AM, Brazil

[3] Egyptian Minist Hlth & Populat, Cairo, Egypt

[4] Fac Martha Falcao, Manaus, AM, Brazil

[5] Secretaria Municipal Saude Manaus, Lab Distrital Sul, Manaus, AM, Brazil

[6] Univ Estado Amazonas, Manaus, AM, Brazil

[7] Fundacao Med Trop Heitor Vieira Dourado, Manaus, AM, Brazil

来源：

REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL | 2023年 / 56卷

关键词：

COVID-19; SARS-CoV-2; Vaccines; Immunogenicity; Coronavirus vaccine; CONTROLLED PHASE-2 TRIAL; SAFETY; ADULTS;

D O I：

10.1590/0037-8682-0661-2021

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

Introduction: Immunogenicity has emerged as a challenge in the development of vaccines against coronavirus disease of 2019 (COVID-19). Immunogenicity is a determinant of the efficacy and safety of vaccines. This systematic review and associated meta-analysis summarized and characterized the immunogenicity of COVID-19 vaccines in randomized controlled trials (RCTs). Methods: Relevant RCTs were systematically sourced from different medical databases in August 2021. The risk ratios and mean differences with 95% confidence intervals were calculated. Results: Of 2,310 papers, 16 RCTs were eligible for review. These RCTs involved a total of 26,698 participants (15,292 males and 11,231 females). The pooled results showed a significant difference in the geometric mean titer between the vaccinated and control groups in favor of the vaccine group after 1 and 2 months of follow-up, for the young age group (18 -< 55y), and with different doses (P < 0.001). The difference in the older age group (>55y) was insignificant (P = 0.24). The seroconversion rate of spike neutralizing antibodies favored the vaccine groups 1 or 2 months after vaccination (P < 0.001). The seroconversion rate of the vaccine group was significantly different (P < 0.001) from that of the control group. Conclusions: Vaccination elicits immunogenicity in the follow-up period for all age groups and at low and large doses. Therefore, people should be encouraged to receive vaccines currently being offered. A boost dose has been asserted for the elderly.

引用

页数：14

共 44 条

[1] SARS-CoV-2 Vaccines: Status Report [J].

Amanat, Fatima ;

Krammer, Florian .

IMMUNITY, 2020, 52 (04) :583-589

[2] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[3]

Berger A., 2011, Cochrane Handb Syst Rev Interv, V1st, P3

[4] Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques [J].

Bewley, Kevin R. ;

Gooch, Karen ;

Thomas, Kelly M. ;

Longet, Stephanie ;

Wiblin, Nathan ;

Hunter, Laura ;

Chan, Kin ;

Brown, Phillip ;

Russell, Rebecca A. ;

Ho, Catherine ;

Slack, Gillian ;

Humphries, Holly E. ;

Alden, Leonie ;

Allen, Lauren ;

Aram, Marilyn ;

Baker, Natalie ;

Brunt, Emily ;

Cobb, Rebecca ;

Fotheringham, Susan ;

Harris, Debbie ;

Kennard, Chelsea ;

Leung, Stephanie ;

Ryan, Kathryn ;

Tolley, Howard ;

Wand, Nadina ;

White, Andrew ;

Sibley, Laura ;

Sarfas, Charlotte ;

Pearson, Geoff ;

Rayner, Emma ;

Xue, Xiaochao ;

Lambe, Teresa ;

Charlton, Sue ;

Gilbert, Sarah ;

Sattentau, Quentin J. ;

Gleeson, Fergus ;

Hall, Yper ;

Funnell, Simon ;

Sharpe, Sally ;

Salguero, Francisco J. ;

Gorringe, Andrew ;

Carroll, Miles .

SCIENCE ADVANCES, 2021, 7 (37)

[5]

Center for Biologics Evaluation and Research, 2020, EM US AUTH VACC EXPL

[6] Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults [J].

Che, Yanchun ;

Liu, Xiaoqiang ;

Pu, Yi ;

Zhou, Meijian ;

Zhao, Zhimei ;

Jiang, Ruiju ;

Yin, Zhifang ;

Xu, Mingjue ;

Yin, Qiongzhou ;

Wang, Jianfeng ;

Pu, Jing ;

Zhao, Heng ;

Zhang, Ying ;

Wang, Lichun ;

Jiang, Ya ;

Lei, Jin ;

Zheng, Yan ;

Liao, Yun ;

Long, Runxiang ;

Yu, Li ;

Cui, Pingfang ;

Yang, Huijuan ;

Zhang, Yuehui ;

Li, Jingyu ;

Chen, Weiwu ;

He, Zhanlong ;

Ma, Kaili ;

Hong, Chao ;

Li, Dandan ;

Jiang, Guorun ;

Liu, Donglan ;

Xu, Xingli ;

Fan, Shengtao ;

Cheng, Chen ;

Zhao, Hongling ;

Yang, Jianbo ;

Li, Yan ;

Zou, Yanxiang ;

Zhu, Youshuai ;

Zhou, Yaling ;

Guo, Yingqiu ;

Yang, Ting ;

Chen, Hongbo ;

Xie, Zhongping ;

Li, Changgui ;

Li, Qihan .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) :E3949-E3955

[7] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine [J].

Chu, Laurence ;

McPhee, Roderick ;

Huang, Wenmei ;

Bennett, Hamilton ;

Pajon, Rolando ;

Nestorova, Biliana ;

Leav, Brett .

VACCINE, 2021, 39 (20) :2791-2799

[8]

Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]

[9] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J].

Folegatti, Pedro M. ;

Ewer, Katie J. ;

Aley, Parvinder K. ;

Angus, Brian ;

Becker, Stephan ;

Belij-Rammerstorfer, Sandra ;

Bellamy, Duncan ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Clutterbuck, Elizabeth A. ;

Dold, Christina ;

Faust, Saul N. ;

Finn, Adam ;

Flaxman, Amy L. ;

Hallis, Bassam ;

Heath, Paul ;

Jenkin, Daniel ;

Lazarus, Rajeka ;

Makinson, Rebecca ;

Minassian, Angela M. ;

Pollock, Katrina M. ;

Ramasamy, Maheshi ;

Robinson, Hannah ;

Snape, Matthew ;

Tarrant, Richard ;

Voysey, Merryn ;

Green, Catherine ;

Douglas, Alexander D. ;

Hill, Adrian V. S. ;

Lambe, Teresa ;

Gilbert, Sarah C. ;

Pollard, Andrew J. .

LANCET, 2020, 396 (10249) :467-478

[10] Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19 [J].

Han, Yang ;

Liu, Peipei ;

Qiu, Yang ;

Zhou, Jie ;

Liu, Ying ;

Hu, Xujuan ;

Yang, Qingyu ;

Huang, Rui ;

Wen, Xinyue ;

Song, Hao ;

Yu, Pengcheng ;

Yang, Mengjie ;

Zhang, Jing ;

Liu, William J. ;

Peng, Ke ;

Wu, Guizhen ;

Zhang, Dingyu ;

Zhou, Xi ;

Wu, Ying .

JCI INSIGHT, 2021, 6 (04)

← 1 2 3 4 5 →